The state of Iowa currently has 4 active clinical trials seeking participants for Type 1 Diabetes research studies. These trials are conducted in various cities, including Iowa City, Des Moines, Sioux City and West Des Moines.
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133
Recruiting
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
Type 1 Diabetes Extension Study
NCT02734277
Recruiting
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for... Read More
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
04/09/2025
Locations: University of Iowa Health Care Division of Pediatric Endocrinology, Iowa City, Iowa
Conditions: Type 1 Diabetes Mellitus, T1DM, T1D
Register for Updates
A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes
NCT05018585
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
ALL
Ages:
Between 12 years and 28 years
Trial Updated:
03/11/2025
Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa
Conditions: Type 1 Diabetes Mellitus
Register for Updates